Evaluating only Otonomy’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Market timing.
Key Events Timeline
FOUNDING
MILESTONE
CRISIS
SHUTDOWN
Full Analysis
Free · no account needed
Documented cause
Otonomy developed sustained-release drug formulations for inner ear disorders including labyrinthitis and tinnitus. The company raised $355M and listed on Nasdaq. When OTO-313, the lead tinnitus drug, failed to show efficacy in Phase 2 trials in 2021, the company had no pipeline to fall back on. Otonomy announced a full shutdown in January 2022.
Lesson
“Hearing health is a massively underserved market but requires multiple mechanisms in parallel — tinnitus has failed dozens of drug programs.”